Tag: merger
-
Baxter Acquires Sickle-Cell Prevention Drug Developer
10 July 2014. Baxter International in Deerfield, Illinois is acquiring AesRx LLC, a biopharmaceutical company in Newton, Massachusetts developing drugs for sickle-cell and other rare diseases. Baxter is making an initial payment to AesRx, which will be eligible for future payments tied to development and commercial milestones, but dollar amounts were not disclosed. Sickle cell…
-
Remote Heart Failure Monitoring Device Approved by FDA
29 May 2014. The U.S. Food and Drug Administration yesterday approved an implanted device that measures pulmonary artery pressure and heart rate of patients with moderate heart failure who were hospitalized in the previous year. The device, the CardioMEMS HF System, is made by CardioMEMS Inc. in Atlanta. St. Jude Medical, a medical device manufacturer…
-
Baxter Acquiring Hemophilia Gene-Therapy Biotech Company
3 April 2014. Baxter International, a pharmaceutical and medical products company in Deerfield, Illinois is buying Chatham Therapeutics LLC, a developer of gene therapy to treat hemophilia. Under the agreement, Baxter will acquire outstanding LLC interests in Chatham for $70 million, but future milestone payments are also possible. The acquisition gives Baxter access to all…
-
Bristol-Myers Squibb, Biotech in Cancer Drug Discovery Deal
17 March 2014. Bristol-Myers Squibb, a pharmaceutical company in New York, and Five Prime Therapeutics in South San Francisco, California are collaborating in discovery of cancer immunotherapies. The deal can be worth as much as $350 million to Five Prime Therapeutics, in which Bristol-Myers Squibb will also get a 5 percent stake. Five Prime Therapeutics…
-
Myriad Genetics Acquires Rheumatoid Arthritis Test Developer
Myriad Genetics Inc., a designer of genetics-based diagnostics in Salt Lake City, will acquire Crescendo Bioscience in South San Francisco, California, a developer of molecular blood tests for autoimmune diseases, particularly rheumatoid arthritis. Myriad is paying $270 million in cash, which includes repayment of an outstanding $25 million loan to Crescendo. Crescendo Bioscience, founded in…
-
Becton Dickinson Acquires Point-of-Care Diagnostics Maker
Becton, Dickinson and Company, a medical device manufacturer in Franklin Lakes, New Jersey is buying Alverix Inc., a developer of point-of-care diagnostics equipment in San Jose, California. The purchase price is $40 million, according to a Becton Dickinson statement. Alverix designs testing equipment for physician’s offices, retail and mobile clinics, rural settings, and homes that…
-
Bayer Acquires Cancer Drug Developer Algeta for $2.9B
The global pharmaceutical company Bayer Group based in Germany is buying the specialty drug company Algeta ASA in Oslo, Norway for NOK 17.6 billion (USD 2.9 billion). Algeta, developer of a radium-based drug to treat prostate cancer, says its board of directors approved the sale, subject to confirmation by shareholders. Bayer and Algeta collaborated on…
-
St. Jude Medical Acquires Leadless Pacemaker Developer
St. Jude Medical, a medical device company in St. Paul, Minnesota, is acquiring Nanostim Inc., a developer of self-contained leadless heart pacemakers in Sunnyvale, California. Shareholders in the privately owned Nanostim can receive up to $188.5 million in upfront cash and milestone payments as a result of the purchase. St. Jude Medical has a relationship…
-
Medtronic Acquires Telemedicine Systems Developer
Medtronic Inc., a medical device company in Minneapolis, Minnesota, is buying Cardiocom, a developer of telemedicine systems in nearby Chanhassen, Minnesota, in an all-cash transaction valued at $200 million. Medtronic’s devices currently help treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal disorders. Cardiocom, founded in 1999 and privately held, builds solutions for home…
-
Actelion to Acquire Developer of Rare Cancer Treatment
Actelion Ltd, a biopharmaceutical company based in Switzerland, acquired Ceptaris Therapeutics Inc., a specialty pharmaceutical developer in Malvern, Pennsylvania, in a deal with a potential value of at least $250 million. The acquisition, however, depends on the U.S. Food and Drug Administration approving Ceptaris’s only current product, a topical treatment for symptoms from a rare…